Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

@article{Nemunaitis1998CombinedAO,
  title={Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.},
  author={John Nemunaitis and Chris Poole and John Neil Primrose and Alexander Rosemurgy and John H. Malfetano and Peter E. Brown and Amy Berrington and Anne Cornish and Kevin Lynch and Henning Rasmussen and D R Kerr and DerrickD. Cox and Audrey Millar},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1998},
  volume={4 5},
  pages={1101-9}
}
This combined analysis investigated the effect of marimastat, a specific inhibitor of matrix metalloproteinases, on markers of tumor progression measured in patients with advanced cancer. By defining the tolerability and biological activity of the drug, it aimed to establish an appropriate dose range for use in Phase III trials. Patients with advanced, serologically progressive ovarian, prostatic, pancreatic, and colorectal cancer were recruited into six nonrandomized, dose ranging, multicenter… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

An introduction to categorical data analysis

  • A. Agresti
  • Wiley Series in Probability and Statistics,
  • 1996

Recent advances in matrix metalloproteinase inhibitor research

  • R. P. Beckett, A. H. Davidson, A. H. Drummond, P. Huxley, M. Whittaker
  • Drug Dcv . Today
  • 1996

Similar Papers

Loading similar papers…